Zimmer Biomet (NYSE:ZBH) Announces Earnings Results

Zimmer Biomet (NYSE:ZBH) released its earnings results on Wednesday. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02, Zacks reports. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter last year, the company earned $1.74 earnings per share. Zimmer Biomet’s quarterly revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet updated its FY 2025 guidance to 8.100-8.300 EPS.

Zimmer Biomet Trading Down 14.7%

ZBH traded down $15.19 during midday trading on Wednesday, hitting $87.99. The company’s stock had a trading volume of 6,544,658 shares, compared to its average volume of 1,908,715. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The firm has a market cap of $17.43 billion, a P/E ratio of 21.40, a PEG ratio of 2.29 and a beta of 0.67. The firm has a 50-day moving average price of $101.22 and a two-hundred day moving average price of $97.67. Zimmer Biomet has a 52-week low of $85.84 and a 52-week high of $114.72.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were issued a $0.24 dividend. The ex-dividend date was Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s payout ratio is 23.36%.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several hedge funds and other institutional investors have recently modified their holdings of ZBH. Headlands Technologies LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at about $37,000. State of Wyoming acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at about $124,000. Federated Hermes Inc. lifted its stake in shares of Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 1,202 shares in the last quarter. Brighton Jones LLC acquired a new position in Zimmer Biomet during the 4th quarter worth approximately $204,000. Finally, Chapman Financial Group LLC acquired a new position in Zimmer Biomet during the 2nd quarter worth approximately $218,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of recent analyst reports. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Stifel Nicolaus set a $110.00 price target on Zimmer Biomet in a research report on Wednesday. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research report on Thursday, September 18th. Raymond James Financial raised their price target on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Finally, Evercore ISI dropped their price target on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research report on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $110.56.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.